Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Un estudio para probar si BI 1839100 mejora la tos en personas con fibrosis pulmonar idiopática o fibrosis pulmonar progresiva

28 de agosto de 2026 actualizado por: Boehringer Ingelheim

Un estudio de búsqueda de dosis de grupos paralelos, aleatorizado, doble ciego, de fase IIa / IIb para examinar la eficacia y seguridad de BI 1839100 administrado por vía oral durante un período de tratamiento de 12 semanas en pacientes con fibrosis pulmonar idiopática o fibrosis pulmonar progresiva Con tos clínicamente significativa

Adults 40 years of age and older with idiopathic pulmonary fibrosis (IPF) or 18 years and older with progressive pulmonary fibrosis (PPF) can participate in this study. Only people who have a chronic cough can take part. The purpose of this study is to find out how well BI 1839100 helps reduce coughing in people with IPF or PPF.

Participants who have IPF are put into 4 groups by chance. Participants in 3 groups get different doses of BI 1839100. Participants in 1 group get placebo. Placebo looks like BI 1839100 but does not contain any medicine. Participants take the treatment for 3 months. After 1 month of treatment, participants who take the highest dose will have coughing measured to find out if the medicine works. If it does not work, the study may be stopped. Participants who have IPF are in the study for slightly longer than 4 months. During this time, they visit the study site 7 times. This study will also measure the effects of BI 1839100 on coughing and lung function in a smaller group of people with PPF.

During the study, coughing is measured over 24 hours about once per month using a portable device given to participants to use during the study. Participants fill in questionnaires about their coughing. Doctors also perform breathing tests that measure how well the lungs are working at the site visits. Researchers compare the results between participants who take BI 1839100 and placebo. The doctors also regularly check participants' health and take note of any unwanted effects.

Descripción general del estudio

Tipo de estudio

Intervencionista

Inscripción (Actual)

85

Fase

  • Fase 2

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

      • Aachen, Alemania, 52074
        • Universitätsklinikum Aachen, AöR
      • Bamberg, Alemania, 96049
        • CIMS Studienzentrum Bamberg GmbH
      • Essen, Alemania, 45239
        • Ruhrlandklinik, Westdeutsches Lungenzentrum am Universitätsklinikum Essen gGmbH
      • Freiburg im Breisgau, Alemania, 79106
        • Universitätsklinikum Freiburg
      • Hanover, Alemania, 30625
        • Medizinische Hochschule Hannover
      • Heidelberg, Alemania, 69126
        • Thoraxklinik-Heidelberg gGmbH am Universitätsklinikum Heidelberg
      • Solingen, Alemania, 42699
        • Krankenhaus Bethanien gGmbH
    • Tasmania
      • Launceston, Tasmania, Australia, 7250
        • Launceston Respiratory & Sleep Centre
    • Victoria
      • Footscray, Victoria, Australia, 3011
        • Lung Research Victoria
      • Liège, Bélgica, 4000
        • CHR de la Citadelle
    • British Columbia
      • Vancouver, British Columbia, Canadá, V5Z 1M9
        • Gordon & Leslie Diamond Health Care Centre (UBC)
    • Ontario
      • Hamilton, Ontario, Canadá, L8N 4A6
        • St. Joseph's Healthcare Hamilton
    • Quebec
      • Montreal, Quebec, Canadá, H2X 3E4
        • Centre Hospitalier de l'Universite de Montreal (CHUM)
      • Prague, Chequia, 140 59
        • University Thomayer´s Hospital
      • Seoul, Corea del Sur, 05505
        • Asan Medical Center
      • Seoul, Corea del Sur, 01757
        • Inje University Sanggye Paik Hospital
      • Odense, Dinamarca, 5000
        • Odense University Hospital
      • Barcelona, España, 08035
        • Hospital Universitari Vall d'Hebron
      • Galdakao, España, 48960
        • Hospital de Galdakao
      • Málaga, España, 29010
        • Hospital Universitario Virgen de la Victoria
      • Oviedo, España, 33011
        • Hospital Central de Asturias
      • Pozuelo de Alarcón, España, 28223
        • Hospital Quirónsalud Madrid
    • Alabama
      • Birmingham, Alabama, Estados Unidos, 35294
        • University of Alabama at Birmingham
    • Colorado
      • Lakewood, Colorado, Estados Unidos, 80228
        • Critical Care, Pulmonary and Sleep Associates
    • Florida
      • Kissimmee, Florida, Estados Unidos, 34746
        • Clinical Research Specialists LLC - Kissimmee
    • Iowa
      • West Des Moines, Iowa, Estados Unidos, 50266
        • The Iowa Clinic, PC
    • Michigan
      • Warren, Michigan, Estados Unidos, 48088
        • Advanced Pulmonary Research
    • Mississippi
      • Gulfport, Mississippi, Estados Unidos, 39501
        • Memorial Hospital Gulfport
    • New York
      • Mount Kisco, New York, Estados Unidos, 10549
        • Northern Westchester Hospital
      • New York, New York, Estados Unidos, 10029
        • Icahn School of Medicine at Mount Sinai
      • New York, New York, Estados Unidos, 10032
        • Columbia University Medical Center-New York Presbyterian Hospital
    • North Carolina
      • Durham, North Carolina, Estados Unidos, 27710
        • Duke University Medical Center
      • New Bern, North Carolina, Estados Unidos, 28562
        • Coastal Carolina Health Care, P.A. Pulmonary and Sleep Medicine
      • Winston-Salem, North Carolina, Estados Unidos, 27103
        • Southeastern Research Center-Winston Salem-69289
    • Pennsylvania
      • DuBois, Pennsylvania, Estados Unidos, 15801
        • Clinical Research Associates of Central PA
      • Philadelphia, Pennsylvania, Estados Unidos, 19140
        • Temple University Hospital
    • South Carolina
      • Charleston, South Carolina, Estados Unidos, 29406
        • Lowcountry Lung and Critical Care
      • Spartanburg, South Carolina, Estados Unidos, 29303
        • Spartanburg Medical Research
    • Texas
      • Edinburg, Texas, Estados Unidos, 78539
        • A & A Research Consultants, LLC
    • Virginia
      • Richmond, Virginia, Estados Unidos, 23230
        • Pulmonary Associates of Richmond, Inc.
      • Helsinki, Finlandia, 00029
        • HYKS Keuhkosairauksien tutkimusyksikkö
      • Oulu, Finlandia, 90220
        • Oulun yliopistollinen keskussairaala
      • Turku, Finlandia, 20520
        • TYKS
      • Angers, Francia, 49933
        • HOP d'Angers
      • Bobigny, Francia, 93000
        • HOP Avicenne
      • Caen, Francia, 14033
        • HOP CHU Caen
      • La Tronche, Francia, 38700
        • HOP Michallon
      • Nantes, Francia, 44093
        • HOP Nord Laennec
      • Tours, Francia, 37000
        • HOP Bretonneau
      • Crete, Grecia, 71500
        • Hospital of Heraklion (PAGNI)
      • Pátrai, Grecia, 26504
        • Univ. Gen. Hosp. of Patras
      • Milan, Italia, 20123
        • Ospedale Classificato San Giuseppe
      • Padova, Italia, 35128
        • Azienda Ospedaliera Universitaria di Padova
      • Roma, Italia, 00168
        • Fondazione Policlinico Universitario Agostino Gemelli IRCCS
      • Roma, Italia, 00133
        • Pol. Universitario Tor Vergata
      • Fukui, Yoshida-gun, Japón, 910-1193
        • University of Fukui Hospital
      • Fukuoka, Fukuoka, Japón, 810-8563
        • National Hospital Organization Kyushu Medical Center
      • Fukuoka, Fukuoka, Japón, 812-8582
        • Kyushu University Hospital
      • Hokkaido, Sapporo, Japón, 060-8543
        • Sapporo Medical University Hospital
      • Hyogo, Himeji, Japón, 670-8520
        • National Hospital Organization Himeji Medical Center
      • Kanagawa, Yokohama, Japón, 236-0051
        • Kanagawa Cardiovascular and Respiratory Center
      • Tokushima, Tokushima, Japón, 770-8503
        • Tokushima University Hospital
      • Tokyo, Ota-ku, Japón, 143-8541
        • Toho University Omori Medical Center
      • Tokyo, Shinjuku-ku, Japón, 162-8655
        • National Center for Global Health and Medicine
      • Kajang, Malasia, 43000
        • Hospital Sultan Idris Shah Serdang
      • Kuala Lumpur, Malasia, 53000
        • Institut Perubatan Respiratori
      • Bergen, Noruega, N-5021
        • Haukeland Universitetssykehus
      • Lørenskog, Noruega, 1478
        • Akershus Universitetssykehus HF
      • Oslo, Noruega, N-0372
        • Oslo Universitetssykehus HF, Rikshospitalet
      • Christchurch, Nueva Zelanda, 8011
        • Christchurch Hospital
      • Hamilton, Nueva Zelanda, 3240
        • Waikato Hospital
      • One Tree Hill, Auckland, Nueva Zelanda, 1051
        • Greenlane Clinical Centre
      • Breda, Países Bajos, 4818 CK
        • Amphia Ziekenhuis
      • Rotterdam, Países Bajos, 3015 GD
        • Erasmus Medisch Centrum-ROTTERDAM-50697
      • Changsha, Porcelana, 410011
        • The Second Xiangya Hospital Of Central South University
      • Chengdu, Porcelana, 610041
        • West China Hospital, Sichuan University
      • Chengdu, Porcelana, 610072
        • People's Hospital of Sichuan Province
      • Guangzhou, Porcelana, 510120
        • First Affiliated Hospital of Guangzhou Medical University
      • Hangzhou, Porcelana, 310013
        • Zhejiang Hospital
      • Hefei, Porcelana, 230001
        • Anhui Provincial Hospital
      • Nanjing, Porcelana, 210008
        • Nanjing Drum Tower Hospital
      • Shanghai, Porcelana, 200433
        • Shanghai Pulmonary Hospital
      • Shenyang, Porcelana, 110000
        • China Shenyang Chest Hospital
      • Tianjin, Porcelana, 30052
        • Tianjin Medical University General Hospital
      • Xuzhou, Porcelana, 221009
        • Affiliated Hospital, Xuzhou Medical college
      • Exeter, Reino Unido, EX2 5DW
        • Royal Devon and Exeter Hospital, Wonford
      • Lancaster, Reino Unido, LA1 4RP
        • Royal Lancaster Infirmary
      • London, Reino Unido, SW3 6NP
        • Royal Brompton Hospital
      • Manchester, Reino Unido, M23 9LT
        • Wythenshawe Hospital
      • Southampton, Reino Unido, SO16 6YD
        • Southampton General Hospital
      • Singapore, Singapur, 169608
        • Singapore General Hospital
      • Lund, Suecia, 221 85
        • Skånes universitetssjukhus, Lund
      • Uppsala, Suecia, 752 37
        • CTC Clinical Trial Consultants AB
      • Bangkok, Tailandia, 10330
        • Chulalongkorn Hospital
      • Khon Kaen, Tailandia, 40002
        • Srinagarind Hospital
      • Ratchatewi, Tailandia, 10400
        • Ramathibodi Hospital
      • Songkhla, Tailandia, 90110
        • Songklanagarind Hospital
      • Kaohsiung City, Taiwán, 807
        • Kaohsiung Medical University Chung-Ho Memorial Hospital
      • Taichung, Taiwán, 40705
        • Taichung Veterans General Hospital

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria

For Idiopathic Pulmonary Fibrosis (IPF) cohort:

  • Minimum age: 40 years

  • Diagnosis of IPF

  • Chronic cough (>8 weeks prior to Visit 1) attributed to IPF and refractory to treatment for known causes (Principal Investigator (PI) assessment)

  • Cough Severity visual analogue scale (VAS) ≥30 mm at Visit 1 and Visit 2B

  • Forced vital capacity (FVC) ≥45% of predicted normal at Visit 1

  • Diffusing capacity of the lungs for carbon monoxide (DLCO) >25% of predicted normal at Visit 1

  • Patients may be either:

    • On stable therapy with nintedanib or pirfenidone for ≥12 weeks prior to Visit 1 and are planning to stay on this background treatment for the whole trial duration. Combination of nintedanib plus pirfenidone will not be allowed
    • Not on therapy with nintedanib or pirfenidone for ≥12 weeks prior to Visit 1 (either antifibrotic (AF)-treatment naïve or previously discontinued) and do not plan to start or re-start AF treatment during the trial. It is not permitted to delay nintedanib or pirfenidone therapy for the purpose of participating in this trial
  • Patients aged ≥40 years when signing the informed consent

For Progressive Pulmonary Fibrosis (PPF) cohort:

  • Minimum age: 18 years

  • Diagnosis of PPF

  • Chronic cough (>8 weeks prior to Visit 1) attributed to PPF, refractory to treatment for known causes (PI assessment)

  • Cough Severity VAS ≥30 mm at Visit 1 and Visit 2B

  • FVC ≥45% of predicted normal at Visit 1

  • DLCO ≥25% of predicted normal at Visit 1

  • If receiving immunomodulatory therapy for interstitial lung disease (ILD), allowed medications include tacrolimus, mycophenolate mofetil, or azathioprine (stable dose for 12 weeks prior to Visit 1)

  • Patients may be either:

    • On a stable therapy with nintedanib for ≥12 weeks prior to Visit 1 and are planning to stay on this background treatment for the whole trial duration
    • Not on a therapy with nintedanib for ≥12 weeks prior to Visit 1 (either AF-treatment naïve or previously discontinued) and do not plan to start or re-start AF treatment during the trial. It is not permitted to delay nintedanib or pirfenidone therapy for the purpose of participating in this trial
  • Patients aged >18 years when signing the informed consent Further inclusion criteria apply.

Exclusion criteria for IPF and PPF cohorts:

  • Acute exacerbation of IPF/PPF within 12 weeks prior to Visit 1
  • Forced expiratory volume in 1 second (Forced expiratory volume in 1 second (FEV1))/FVC <0.7 at Visit 1
  • Known reversible airflow obstruction/response to bronchodilators
  • In the opinion of the Investigator, other clinically significant pulmonary abnormalities, including primary bronchitic and bronchiectatic disorder
  • Upper or lower respiratory tract infection within 4 weeks prior to Visit 1
  • Ongoing chronic pulmonary infection (e.g. mycobacterial or fungal disease)
  • Current smokers (tobacco use within the 6 months prior to Visit 1)
  • Initiation or change in supplemental oxygen requirement during 4 weeks prior to Visit 1 Further exclusion criteria apply.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Cuadruplicar

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Comparador de placebos: IPF placebo

Participants with idiopathic pulmonary fibrosis (IPF) with clinically meaningful cough with background antifibrotic treatment on stable dose (for >12 weeks) or without antifibrotic treatment administered orally placebo matching BI 1839100 as tablets. Participants were planned to be treated for 12 weeks.

Placebo

Experimental: IPF BI 1839100 low dose

Participants with idiopathic pulmonary fibrosis (IPF) with clinically meaningful cough with background antifibrotic treatment on stable dose (for >12 weeks) or without antifibrotic treatment administered orally low doses of BI 1839100 as tablets. Additionally, as needed, participants administered placebo tablets to maintain the blinding. Participants were planned to be treated for 12 weeks.

Placebo

BI 1839100

Experimental: IPF BI 1839100 medium dose

Participants with idiopathic pulmonary fibrosis (IPF) with clinically meaningful cough with background antifibrotic treatment on stable dose (for >12 weeks) or without antifibrotic treatment administered orally medium doses of BI 1839100 as tablets. Additionally, as needed, participants administered placebo tablets to maintain the blinding. Participants were planned to be treated for 12 weeks.

Placebo

BI 1839100

Experimental: IPF BI 1839100 high dose

Participants with idiopathic pulmonary fibrosis (IPF) with clinically meaningful cough with background antifibrotic treatment on stable dose (for >12 weeks) or without antifibrotic treatment administered orally high doses of BI 1839100 as tablets. Participants were planned to be treated for 12 weeks.

BI 1839100

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Phase IIa: Change From Baseline in 24-h Cough Frequency (CC/h) at Week 4
Periodo de tiempo: At baseline (closest measurement prior to randomisation) and Week 4.

The raw Cough count (CC) over 24 h was standardised to CC per hour, and then log-transformed (natural log). The analysis was a restricted maximum likelihood (REML) based approach using a mixed model with repeated measurements (MMRM). The analysis included the fixed categorical effects of treatment, background antifibrotic (AF) treatment (Yes, No), and the fixed continuous effects of baseline. Visits were treated as the repeated measure with an unstructured covariance structure used to model the within-participant measurements. Intercurrent events were handled with the treatment policy approach, which uses the value of the endpoint regardless of the occurrence of the intercurrent event. Adjusted estimates for relative change from baseline (reported here) were calculated by 100*(exp(diff)-1) where diff is the difference from baseline in log-transformed values.

At baseline (closest measurement prior to randomisation) and Week 4.
Phase IIb: Change From Baseline in 24-h Cough Frequency (CC/h) at Week 12
Periodo de tiempo: The MMRM model incorporates CC from baseline (closest measurement prior to randomisation), Week 4, Week 8, and Week 12. The data represent the estimated mean change from baseline at Week 12.

The raw Cough count (CC) over 24 h was standardised to CC per hour, and then log-transformed (natural log). The analysis was a restricted maximum likelihood (REML) based approach using a mixed model with repeated measurements (MMRM). The analysis included the fixed categorical effects of treatment, background AF treatment (Yes, No), and the fixed continuous effects of baseline. Visits were treated as the repeated measure with an unstructured covariance structure used to model the within-participant measurements. Intercurrent events were handled with the treatment policy approach, which uses the value of the endpoint regardless of the occurrence of the intercurrent event. Adjusted estimates for relative change from baseline (reported here) were calculated by 100*(exp(diff)-1) where diff is the difference from baseline in log-transformed values.

The MMRM model incorporates CC from baseline (closest measurement prior to randomisation), Week 4, Week 8, and Week 12. The data represent the estimated mean change from baseline at Week 12.

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Phase IIa: Absolute Change From Baseline in Cough Severity Numerical Rating Scale (NRS) Score at Week 4
Periodo de tiempo: At baseline (last measurement prior to the start of trial treatment) and at Week 4.

The Cough Severity NRS is a single-item patient reported outcome measure to assess cough severity on a 11-point numerical rating scale ranging from 0 (no cough) to 10 (worst possible cough) with a recall period of the past 7 days. Higher scores indicate higher severity of cough. The analysis was a REML based approach using a MMRM. The analysis included the fixed categorical effects of treatment, background AF treatment (Yes, No), and the fixed continuous effects of baseline. Visits were treated as the repeated measure with an unstructured covariance structure used to model the within-participant measurements. Intercurrent events were handled with the treatment policy approach, which uses the value of the endpoint regardless of the occurrence of the intercurrent event.

At baseline (last measurement prior to the start of trial treatment) and at Week 4.
Phase IIa: Absolute Change From Baseline in Cough Severity Visual Analog Scale (VAS) Score (Millimeter) at Week 4
Periodo de tiempo: At baseline (last measurement prior to the start of trial treatment) and at Week 4.

The Cough Severity VAS is a single-item patient reported outcome measure to assess cough severity with a visual analogue scale as response option and a recall period of the past 7 days. It is scored according to the distance between no cough (0) and the mark set by the participant on a line based on to the overall severity of the cough in the previous week, with the maximum being 100. Higher distance indicates higher severity of cough. The analysis was a REML based approach using a MMRM. The analysis included the fixed categorical effects of treatment, background AF treatment (Yes, No), and the fixed continuous effects of baseline. Visits were treated as the repeated measure with an unstructured covariance structure used to model the within-participant measurements. Intercurrent events were handled with the treatment policy approach, which uses the value of the endpoint regardless of the occurrence of the intercurrent event.

At baseline (last measurement prior to the start of trial treatment) and at Week 4.
Phase IIb: Absolute Change From Baseline in Cough Severity Numerical Rating Scale (NRS) Score at Week 12
Periodo de tiempo: The MMRM model incorporates values from baseline (last measurement prior to the start of trial treatment), Week 4, Week 8, and Week 12. The data represent the estimated mean change from baseline at Week 12.

The Cough Severity NRS is a single-item patient reported outcome measure to assess cough severity on a 11-point numerical rating scale ranging from 0 (no cough) to 10 (worst possible cough) with a recall period of the past 7 days. Higher scores indicate higher severity of cough. The analysis was a REML based approach using a MMRM. The analysis included the fixed categorical effects of treatment, background AF treatment (Yes, No), and the fixed continuous effects of baseline. Visits were treated as the repeated measure with an unstructured covariance structure used to model the within-participant measurements. Intercurrent events were handled with the treatment policy approach, which uses the value of the endpoint regardless of the occurrence of the intercurrent event.

The MMRM model incorporates values from baseline (last measurement prior to the start of trial treatment), Week 4, Week 8, and Week 12. The data represent the estimated mean change from baseline at Week 12.
Phase IIb: Absolute Change From Baseline in Cough Severity Visual Analog Scale (VAS) Score (Millimeter) at Week 12
Periodo de tiempo: The MMRM model incorporates values from baseline (last measurement prior to the start of trial treatment), Week 4, Week 8, and Week 12. The data represent the estimated mean change from baseline at Week 12.

The Cough Severity VAS is a single-item patient reported outcome measure to assess cough severity with a visual analogue scale as response option and a recall period of the past 7 days. It is scored according to the distance between no cough (0) and the mark set by the participant on a line based on to the overall severity of the cough in the previous week, with the maximum being 100. Higher distance indicates higher severity of cough. The analysis was a REML based approach using a MMRM. The analysis included the fixed categorical effects of treatment, background AF treatment (Yes, No), and the fixed continuous effects of baseline. Visits were treated as the repeated measure with an unstructured covariance structure used to model the within-participant measurements. Intercurrent events were handled with the treatment policy approach, which uses the value of the endpoint regardless of the occurrence of the intercurrent event.

The MMRM model incorporates values from baseline (last measurement prior to the start of trial treatment), Week 4, Week 8, and Week 12. The data represent the estimated mean change from baseline at Week 12.
Phase IIb: Cough Responder Status, Defined as a ≥30% 24-h Cough Frequency Reduction (CC/h) From Baseline at Week 12
Periodo de tiempo: At baseline (last measurement prior to the start of trial treatment) and at Week 12.

The proportions of participants achieving a ≥30% 24-h cough frequency reduction (CC/h) at Week 12 is summarized. The % was calculated as: (number of participants with positive response)/(number of participants in group)*100. Confidence intervals were based on the Wilson method. Intercurrent events are handled with the treatment policy approach, which uses the value of the endpoint regardless of the occurrence of the intercurrent event.

At baseline (last measurement prior to the start of trial treatment) and at Week 12.
Phase IIb: Absolute Change From Baseline in Forced Vital Capacity (FVC) at Week 12
Periodo de tiempo: The MMRM model incorporates values from baseline (last measurement prior to the start of trial treatment), Week 4, Week 8, and Week 12. The data represent the estimated mean change from baseline at Week 12.

FVC was assessed using standardised spirometry equipment. The analysis was a REML based approach using a MMRM. The analysis included the fixed categorical effects of treatment, background AF treatment (Yes, No), and the fixed continuous effects of baseline. Visits were treated as the repeated measure with an unstructured covariance structure used to model the within-participant measurements. Intercurrent events were handled with the treatment policy approach, which uses the value of the endpoint regardless of the occurrence of the intercurrent event.

The MMRM model incorporates values from baseline (last measurement prior to the start of trial treatment), Week 4, Week 8, and Week 12. The data represent the estimated mean change from baseline at Week 12.
Phase IIb: Absolute Change From Baseline in Leicester Cough Questionnaire (LCQ) Physical Domain Score at Week 12
Periodo de tiempo: The MMRM model incorporates values from baseline (last measurement prior to the start of trial treatment), Week 4 and Week 12. The data represent the estimated mean change from baseline at Week 12.

The LCQ is a 19-item patient reported outcome measure that assesses the impact of cough on various aspects of Quality of life (QoL). It is divided into 3 domains (physical, social and psychological), each scored with a 7-point Likert response scale (1 to 7). The total score is calculated using the sum of the means of each subdomain, and ranges from 3 to 21. A higher score indicates better cough specific QoL. The analysis was a REML based approach using a MMRM. The analysis included the fixed categorical effects of treatment, background AF treatment (Yes, No), and the fixed continuous effects of baseline. Visits were treated as the repeated measure with an unstructured covariance structure used to model the within-participant measurements. Intercurrent events were handled with the treatment policy approach, which uses the value of the endpoint regardless of the occurrence of the intercurrent event.

The MMRM model incorporates values from baseline (last measurement prior to the start of trial treatment), Week 4 and Week 12. The data represent the estimated mean change from baseline at Week 12.
Phase IIb: Absolute Change From Baseline in Living With Pulmonary Fibrosis (L-PF) Symptom Cough Domain Score at Week 12
Periodo de tiempo: At baseline (last measurement prior to the start of trial treatment) and at Week 12.

The Symptom module domain of the L-PF questionnaire assesses 3 domains: dyspnea (items 1-12), cough (items 13-18), and fatigue (items 19-23) in the past 24 h. The module has a 5-point Likert scale (numeric rating scale) with varying response options. The Symptoms domain scores (dyspnoea, cough, and fatigue) are generated as a summary score, the mean of the dimension ratings multiplied by 100. The scores range from 0 to 100, with higher scores indicating a greater impairment. The analysis was a REML based approach using a MMRM. The analysis included the fixed categorical effects of treatment, background AF treatment (Yes, No), and the fixed continuous effects of baseline. Visits were treated as the repeated measure with an unstructured covariance structure used to model the within-participant measurements. Intercurrent events were handled with the treatment policy approach, which uses the value of the endpoint regardless of the occurrence of the intercurrent event.

At baseline (last measurement prior to the start of trial treatment) and at Week 12.

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Enlaces Útiles

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

28 de agosto de 2024

Finalización primaria (Actual)

2 de septiembre de 2025

Finalización del estudio (Actual)

2 de septiembre de 2025

Fechas de registro del estudio

Enviado por primera vez

8 de abril de 2024

Primero enviado que cumplió con los criterios de control de calidad

8 de abril de 2024

Publicado por primera vez (Actual)

11 de abril de 2024

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

23 de septiembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

28 de agosto de 2026

Última verificación

1 de agosto de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • 1490-0004
  • 2023-510249-79-00 (Identificador de registro: CTIS)
  • U1111-1301-1311 (Identificador de registro: WHO Registry (ICTRP))
  • 2023 (Subvención/contrato del NIH de EE. UU.)

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

Once the criteria in section "Time Frame" are fulfilled, researchers can use the following link https://www.clinicalstudies.boehringer-ingelheim.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement".

Furthermore, researchers can request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.

Marco de tiempo para compartir IPD

One year after the approval has been granted by major Regulatory Authorities and after the primary manuscript has been accepted for publication, or after termination of the development program.

Criterios de acceso compartido de IPD

For study documents - upon signing of a 'Document Sharing Agreement'.

For study data - 1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a legal agreement.

Tipo de información de apoyo para compartir IPD

  • PROTOCOLO DE ESTUDIO
  • SAVIA
  • RSC

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir